Ligand to acquire XOMA Royalty for $739 million in cash By Investing.com

Ligand Pharmaceuticals will acquire XOMA Royalty for $39.00 per share in cash, valuing the deal at about $739 million and implying a 14% premium to XOMA’s 30-day VWAP. Ligand also raised 2026 revenue guidance to $270 million-$310 million from $245 million-$285 million and lifted adjusted EPS guidance to $8.50-$9.50 from $8.00-$9.00, while expecting the deal to add $1.50 per share to adjusted EPS in 2027. The transaction has been unanimously approved by both boards and is expected to close in Q3 2026, subject to approvals.

Analysis

This is less about a single asset sale and more about Ligand monetizing its platform premium by converting optionality into visible cash flows. The key second-order effect is that the deal should compress the market’s discount on LGND’s portfolio complexity: once XOMA is absorbed, the market can more cleanly underwrite Ligand’s revenue trajectory and capital deployment, which likely supports a higher multiple if management proves it can recycle proceeds into similarly accretive assets.

For XOMA, the headline cash price likely caps near-term upside, but the CVR creates a non-trivial residual claim that may keep borrow tight until the litigation path is better understood. The more interesting dynamic is that the equity becomes a de facto event-driven stub with limited catalyst risk but asymmetric financing/arbitrage constraints; any widening between spot and deal value is more likely to be driven by regulatory/timing slippage than fundamental deterioration.

Competitively, DAWN and ZVRA read as the most exposed on a relative basis because the added Ligand portfolio deepens its reach into the same rare-disease and specialty-asset ecosystems where small-cap biotechs compete for partnering attention and royalty monetization. If Ligand can demonstrate that it can buy diversified royalty streams at mid-teens premiums and immediately add to EPS, that raises the bar for DAWN/ZVRA to justify standalone valuation without similar balance-sheet support or M&A optionality. The market is also underestimating how this kind of deal can pull forward capital-market consolidation across royalty aggregators and life-science financiers.

The main risk is execution over the next 9-15 months: if financing costs rise, the accretion story can lag, and the market may re-rate the deal as balance-sheet expansion rather than earnings growth. Conversely, if biotech risk appetite weakens, the implied value of the CVR and the broader royalty book could compress even before close, creating an opening for relative-value shorts in weaker royalty names.

Key Decisions for Investors

• Long LGND on any post-announcement consolidation over the next 1-3 weeks; target a 10-15% rerating if management can defend 2027 accretion and no financing surprise emerges.
• Short XOMA against cash/announcement value only if borrow is available and spread widens above a low-single-digit annualized IRR equivalent; cover on any regulatory or litigation-specific headline risk.
• Pair trade: long LGND / short DAWN over 1-3 months to express relative consolidation leadership in specialty biotech monetization; thesis breaks if DAWN announces a materially accretive partnership or buyout.
• Small tactical long ZVRA vs basket of small-cap royalty/rare-disease names for 4-8 weeks if the market starts rewarding platform consolidation; use tight risk limits because the move is valuation-sensitive rather than fundamentals-only.
• If the LGND spread remains wide into the next two quarters, buy LGND calls or call spreads dated past expected closing windows to capture upside from deal completion plus multiple expansion, with defined downside to premium paid.